Repligen Corporation (RGEN) Position Lowered by Adams Diversified Equity Fund Inc.
Adams Diversified Equity Fund Inc. decreased its position in Repligen Corporation (NASDAQ:RGEN) by 15.9% during the second quarter, according to its most recent disclosure with the SEC. The firm owned 17,500 shares of the biotechnology company’s stock after selling 3,300 shares during the period. Adams Diversified Equity Fund Inc. owned 0.05% of Repligen Corporation worth $725,000 as of its most recent filing with the SEC.
A number of other hedge funds also recently bought and sold shares of the company. Ameritas Investment Partners Inc. bought a new stake in Repligen Corporation during the first quarter worth $103,000. Victory Capital Management Inc. boosted its stake in Repligen Corporation by 76.6% in the first quarter. Victory Capital Management Inc. now owns 3,400 shares of the biotechnology company’s stock valued at $120,000 after buying an additional 1,475 shares in the last quarter. State of Alaska Department of Revenue boosted its stake in Repligen Corporation by 2.2% in the first quarter. State of Alaska Department of Revenue now owns 3,740 shares of the biotechnology company’s stock valued at $131,000 after buying an additional 80 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in Repligen Corporation by 31.9% in the first quarter. JPMorgan Chase & Co. now owns 3,755 shares of the biotechnology company’s stock valued at $133,000 after buying an additional 908 shares in the last quarter. Finally, US Bancorp DE boosted its stake in Repligen Corporation by 1.2% in the second quarter. US Bancorp DE now owns 4,629 shares of the biotechnology company’s stock valued at $191,000 after buying an additional 54 shares in the last quarter. 99.02% of the stock is owned by institutional investors.
Shares of Repligen Corporation (RGEN) opened at 41.53 on Monday. Repligen Corporation has a one year low of $26.16 and a one year high of $46.81. The company has a 50-day moving average price of $41.28 and a 200 day moving average price of $36.10. The company has a market capitalization of $1.42 billion, a price-to-earnings ratio of 109.58 and a beta of 1.30.
Repligen Corporation (NASDAQ:RGEN) last announced its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.15 by $0.05. Repligen Corporation had a net margin of 15.61% and a return on equity of 9.90%. The firm had revenue of $32.40 million during the quarter, compared to analysts’ expectations of $31.72 million. During the same period in the prior year, the company posted $0.16 EPS. The company’s revenue was up 11.0% on a year-over-year basis. On average, analysts forecast that Repligen Corporation will post $0.56 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This story was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this story can be viewed at https://www.thecerbatgem.com/2017/08/07/adams-diversified-equity-fund-inc-lowers-stake-in-repligen-corporation-rgen-updated.html.
RGEN has been the subject of several recent research reports. First Analysis reaffirmed an “equal weight” rating and issued a $40.00 price objective on shares of Repligen Corporation in a research report on Friday, April 21st. BidaskClub cut Repligen Corporation from a “strong-buy” rating to a “buy” rating in a report on Wednesday, June 14th. Jefferies Group LLC reiterated a “hold” rating and issued a $40.00 target price (up previously from $33.00) on shares of Repligen Corporation in a report on Wednesday, June 28th. William Blair assumed coverage on Repligen Corporation in a research note on Friday, July 21st. They set an “outperform” rating on the stock. Finally, Zacks Investment Research cut Repligen Corporation from a “buy” rating to a “hold” rating in a research note on Wednesday, July 5th. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $41.20.
About Repligen Corporation
Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.
Receive News & Stock Ratings for Repligen Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Corporation and related stocks with our FREE daily email newsletter.